Neogen reported Q3 FY 2026 revenue of $211.2 million, slightly below analyst expectations, with a GAAP loss of $0.08 per share and adjusted EPS of $0.09. The company delivered positive adjusted profitability and solid cash generation, while headline growth and GAAP earnings remained under pressure, with after‑hours movement not disclosed in the release.
About Neogen
Neogen Corporation (NASDAQ: NEOG) is a food and animal safety company that provides diagnostic test kits and related products to detect contamination in food and feed, as well as animal health solutions. Founded in 1982 and headquartered in Lansing, Michigan, Neogen serves food processors, animal protein producers, and related industries worldwide.
The company’s portfolio spans food safety, animal safety, and allied testing products that help customers manage microbiological, mycotoxin, allergen, and drug residue risks. Neogen has an employee base of roughly 2,900-3,000 people globally and a market capitalization around $1.2-1.9 billion as of early 2026, with no regular dividend and a P/E ratio not meaningful due to recent GAAP losses.
The firm is in the midst of an operational transformation, including a transfer of Petrifilm manufacturing and integration of prior acquisitions, while targeting higher margin, core growth in its key segments.
Top Financial Highlights
- Q3 FY 2026 total revenue was $211.2 million, down about 4.4 percent year over year.
- Food Safety revenue grew 2.6 percent with core growth of 4.0 percent, supported by strength in key product lines.
- Animal Safety revenue declined 20.1 percent, with core growth down 8.7 percent, mainly due to third‑party supplier challenges in the quarter.
- Q3 GAAP net loss was $17.0 million, compared with a net loss of $10.9 million in the prior‑year quarter.
- GAAP diluted EPS was $(0.08) versus $(0.05) in the same quarter last year.
- Adjusted net income was $19.4 million, compared with $20.9 million a year ago.Adjusted diluted EPS was $0.09, slightly below the $0.10 reported in the prior‑year period but above some consensus estimates.
- Gross profit was $99.0 million on cost of revenue of $112.2 million, implying a gross margin in the mid‑40 percent range.
- The company recorded an operating loss of $3.3 million, versus operating income of $5.4 million in the prior year, reflecting higher costs and investment.
- Adjusted EBITDA was $48.2 million, compared with $48.6 million last year, with adjusted EBITDA margin of 22.8 percent up 110 basis points sequentially.
- Operating cash flow was $22.7 million, supporting a free cash flow of $11.1 million for the quarter.
- Cash and cash equivalents stood at $159.9 million at February 28, 2026, up from $129.0 million at May 31, 2025, providing solid liquidity.
- Non‑current debt declined to $793.3 million from $874.8 million, indicating continued deleveraging.
- Management reiterated and raised full‑year fiscal 2026 guidance to revenue of $845–$855 million and adjusted EBITDA of about $175 million, signalling confidence in the remainder of the year.
Beat or Miss?
| Metric | Reported | Difference and analysis |
| Revenue | $211.2 million | Missed analyst estimate of about $212.2 million by roughly $1 million, reflecting softer Animal Safety sales. |
| GAAP diluted EPS | ($0.08) | Below consensus of $(0.05), as higher costs and one‑time items weighed on GAAP earnings. |
| Adjusted EPS | $0.09 | Ahead of some FactSet and other consensus estimates around $0.06, showing better‑than‑expected underlying profitability. |
| Adjusted EBITDA | $48.2 million | In line with market expectations, with margin improvement of 110 bps sequentially. |
What Leadership Is Saying?
“Our third quarter results demonstrate continued progress in our transformation, as Food Safety delivered solid core growth and we advanced the Petrifilm manufacturing transition, even as Animal Safety faced temporary supplier disruptions.”
“We generated strong cash flow from operations of $22.7 million and delivered $48.2 million in adjusted EBITDA with a 22.8 percent margin, which supports our updated fiscal 2026 outlook for $845–$855 million in revenue and approximately $175 million in adjusted EBITDA.”
Historical Performance
| Category | Q3 FY 2026 | Q3 FY 2025 | Change (%) |
| Revenue | $211.2 million | About $221.0 million (implied) | Around -4.4% year over year |
| Net income (GAAP) | $(17.0) million | $(10.9) million | Loss widened by about 56% |
| Adjusted net income | $19.4 million | $20.9 million | Declined roughly 7%. |
| Operating result | $(3.3) million (loss) | $5.4 million (income) | Swing of over $8 million into a loss |
| Adjusted EBITDA | $48.2 million | $48.6 million | Essentially flat, slightly lower year over year. |
Competitors Performance
| Category | Neogen (NEOG) Q3 FY 2026 | Neogen (NEOG) Q3 FY 2025 | Change (%) |
| Revenue | $211.2 million | About $221.0 million | Around -4.4% |
| Net income (GAAP) | $(17.0) million | $(10.9) million | Loss widened about 56 % |
| Operating result | $(3.3) million | $5.4 million | More than $8 million deterioration |
| Category | Neogen Chemicals Q3 FY 2026 | Neogen Chemicals Q3 FY 2025 | Change (%) |
| Revenue from operations | ₹215.6 crore | ₹200.4 crore | About +7% |
| Net profit | ₹8.77 crore | ₹14.41 crore | Around -39% |
| EBITDA | ₹36.30 crore | ₹37.70 crore | Roughly -4% |
How the Market Reacted?
The Q3 FY 2026 release presents a mixed picture: Neogen missed on GAAP earnings and revenue versus consensus but exceeded expectations on adjusted EPS and delivered stable adjusted EBITDA with improving margins.
Cash generation and deleveraging trends are constructive and support a more positive medium‑term narrative, especially with raised full‑year guidance. In the absence of explicit stock price data in the release, the overall tone of the results and outlook leans modestly bullish from a fundamental standpoint, even though near‑term sentiment may remain cautious due to GAAP losses and pressure in Animal Safety.
